Market OverviewTwice-yearly lipid-lowering therapies are reshaping adherence economics in the cardiovascular drugs market by reducing the burden of daily oral medication for high-risk patients. Long-acting RNA interference therapies and other extended-interval treatments can provide durable LDL cholesterol reduction with infrequent administration. The Cardiovascular Drugs Market is projected to...
English
Arabic
French
Spanish
Portuguese
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek